{
  "trial_id": "NCT03170882",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, number of prior lines of therapy, refractory status to lenalidomide, response to prior bortezomib or carfilzomib treatment, measurable disease status (serum M-protein, urine M-protein), venous access suitability, nonhematologic toxicity grade, history of prior autologous stem cell transplantation, history of other malignancies, presence of peripheral neuropathy, recent treatment with investigational products or monoclonal antibodies, gastrointestinal disease status, infection status, HIV/HBV/HCV status, use of cytochrome P-450 3A inducers, history of drug or alcohol abuse, history of severe cutaneous reactions.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment",
        "Baseline Height",
        "Baseline Weight",
        "Baseline Body Surface Area"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "number of prior lines of therapy",
        "refractory status to lenalidomide",
        "response to prior bortezomib or carfilzomib treatment",
        "measurable disease status (serum M-protein, urine M-protein)",
        "venous access suitability",
        "nonhematologic toxicity grade",
        "history of prior autologous stem cell transplantation",
        "history of other malignancies",
        "presence of peripheral neuropathy",
        "recent treatment with investigational products or monoclonal antibodies",
        "gastrointestinal disease status",
        "infection status",
        "HIV/HBV/HCV status",
        "use of cytochrome P-450 3A inducers",
        "history of drug or alcohol abuse",
        "history of severe cutaneous reactions"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, ECOG performance status, Number of prior lines of therapy, Refractory to lenalidomide, Prior bortezomib or carfilzomib treatment, Measurable disease status, Serum M-protein, Urine M-protein, Venous access suitability, Nonhematologic toxicity recovery,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment",
        "Baseline Height",
        "Baseline Weight",
        "Baseline Body Surface Area"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Number of prior lines of therapy",
        "Refractory to lenalidomide",
        "Prior bortezomib or carfilzomib treatment",
        "Measurable disease status",
        "Serum M-protein",
        "Urine M-protein",
        "Venous access suitability",
        "Nonhematologic toxicity recovery"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Number of Prior Lines of Therapy, Prior Lenalidomide Exposure, Prior Bortezomib or Carfilzomib Exposure, Serum M-Protein, Urine M-Protein, Hemoglobin, Platelet Count, Creatinine Clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Baseline Height",
        "Baseline Weight",
        "Baseline Body Surface Area"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG Performance Status",
        "Number of Prior Lines of Therapy",
        "Prior Lenalidomide Exposure",
        "Prior Bortezomib or Carfilzomib Exposure",
        "Serum M-Protein",
        "Urine M-Protein",
        "Hemoglobin",
        "Platelet Count",
        "Creatinine Clearance"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, number of prior lines of therapy, prior therapies, time since diagnosis, serum M-protein level, urine M-protein level, MM isotype, presence of extramedullary disease, presence of high-risk cytogenetics.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Baseline Height",
        "Baseline Weight",
        "Baseline Body Surface Area"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "number of prior lines of therapy",
        "prior therapies",
        "time since diagnosis",
        "serum M-protein level",
        "urine M-protein level",
        "MM isotype",
        "presence of extramedullary disease",
        "presence of high-risk cytogenetics"
      ]
    }
  }
}